News >

Levy Highlights Benefits, Limitations of Liquid Biopsies in NSCLC

Brandon Scalea
Published: Monday, Jul 16, 2018

Dr. Benjamin P. Levy

Benjamin P. Levy, MD
The diagnostic workup in non–small cell lung cancer (NSCLC) has undergone important changes over recent years, but there is still work to be done in improving the “gold standard” of tissue biopsy, said Benjamin P. Levy, MD.

Levy explained that detecting circulating tumor DNA (ctDNA) and performing genomic interrogation are crucial for the diagnosis and ultimate treatment of patients with NSCLC. Sometimes, Levy added, a standard tissue biopsy can confirm a patient’s diagnosis, and corresponding molecular abnormalities, but there is not enough tissue. Therefore, a liquid biopsy is the key to a more sophisticated understanding of a patient’s condition.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Therapies for Patients With ALK-Positive Lung Cancers: More Options…More Decisions…Better OutcomesAug 30, 20191.5
Oncology Briefings™: Treating Advanced NSCLC Without Actionable MutationsAug 30, 20191.0
Publication Bottom Border
Border Publication